Allosteric pathways in nuclear receptors - Potential targets for drug design

Pharmacol Ther. 2018 Mar:183:152-159. doi: 10.1016/j.pharmthera.2017.10.014. Epub 2017 Oct 31.

Abstract

The nuclear receptor family of transcription factor proteins mediates endocrine function and plays critical roles in the development, physiology and pharmacology. Malfunctioning nuclear receptors are associated with several disease states. The functional activity of nuclear receptors is regulated by small molecular hormonal and synthetic molecules. Multiple sources of evidence have identified and distinguished between the different allosteric pathways initiated by ligands, DNA and cofactors such as co-activators and co-repressors. Also, these biophysical studies are attempting to determine how these pathways that regulate co-activator and DNA recognition can control gene transcription. Thus, there is a growing interest in determining the genome-scale impact of allostery in nuclear receptors. Today, it is accepted that a detailed understanding of the allosteric regulatory pathways within the nuclear receptor molecular complex will enable the development of efficient drug therapies in the long term.

Keywords: Allostery; Drug design; Endocrine; Genome-scale; Nuclear receptor; Transcription.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Allosteric Regulation
  • DNA / metabolism
  • Drug Design*
  • Humans
  • Ligands
  • Receptors, Cytoplasmic and Nuclear / metabolism*

Substances

  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • DNA